A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, multicenter, randomized, double blind, placebo controlled, multiple-dose
study designed to evaluate the efficacy, safety, and tolerability of subcutaneously
administered HAE1 in subjects 12-75 years old with moderate to severe asthma whose symptoms
are inadequately controlled with moderate to high-dose ICS and LABA.